 |
9 Products |  |
120 Diseases | | 9 Products |
|
46 Trials |  |
2133 News |  |
| «12...1213141516171819202122...2930» |
- Ovastat (treosulfan) / Medac
[VIRTUAL] Risk Factors for Overall Survival in Children with High Risk Acute Myeloid Leukemia (HR AML) after Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) with Different Intensity of Conditioning Regimens (Poster Hall (Virtual Meeting)) - Nov 5, 2020 - Abstract #ASH2020ASH_4082;
The presence of I-II grade aGVHD had positive effect in MAC. Factors influencing OS in both groups were disease status at the moment of allo-HSCT and performance status before allo-HSCT The use of RIC can be effective in patients, especially those who have undergone allo-HSCT in the 1st remission, while minimizing regimen-related toxicity in children who have undergone previous intensive treatment.
- Campath (alemtuzumab) / Sanofi
[VIRTUAL] Transplantation for Congenital Sideroblastic Anaemia Is Feasible and Offers Outcomes Comparable to Other Transfusion Dependent Anaemias. a Joint Retrospective Study of the Paediatric Diseases and Severe Aplastic Anaemia Working Parties (PDWP/SAAWP) of EBMT (Poster Hall (Virtual Meeting)) - Nov 5, 2020 - Abstract #ASH2020ASH_2908;
Eighty-six percent of cases had serotherapy with ATG or alemtuzumab...There was one case of limited and one of chronic GvHD, giving an incidence of 11% (0-26%) at 12 months and 24 months. In conclusion, whilst HSCT for CSA is a rare occurrence, these data demonstrate that HSCT for this condition is feasible and the outcomes are in keeping with those obtained for transplantation for transfusion dependent anaemias during the same time-period.
- Ovastat (treosulfan) / Medac
[VIRTUAL] Allogeneic Hematopoietic Cell Transplantation with Myeloablative Conditioning Regimen of Reduced Toxicity Is Associated with Favorable Survival in Patients with Secondary Acute Myeloid Leukemia (Poster Hall (Virtual Meeting)) - Nov 5, 2020 - Abstract #ASH2020ASH_2833;
Achievement of CR remains a major predictor of OS in these patients. The choice of alloHCT in this unique patient population of a rather older age and comorbidity index needs to be revisited.
- Ovastat (treosulfan) / Medac
[VIRTUAL] Treosulfan- Versus Melphalan-Based Reduced Intensity Conditioning in Sequential HLA—Haploidentical Transplantation Using Ptcy As GvHD Prophylaxis in High-Risk MDS /AML of the Elderly: A Matched-Pair Analysis (Poster Hall (Virtual Meeting)) - Nov 5, 2020 - Abstract #ASH2020ASH_1278;
Treosulfan-based RIC in haplo-HSCT though might be an alternative in older pts with low leukemic burden. However for disease control its intensity should be reconsidered and all available post-grafting mantainance strategies applied.
- Ovastat (treosulfan) / Medac
[VIRTUAL] Reduced Intensity Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation of AML in CR and MDS—a Systematic Review and Meta-Analysis of Randomized Controlled Trials (Poster Hall (Virtual Meeting)) - Nov 5, 2020 - Abstract #ASH2020ASH_1267;
The treosulfan based MAC has a promising result in one RCT and even causes less NRM than RIC. Nevertheless, studies are scarce and more studies are needed to confirm the result.
- ||| Natesto (testosterone) / Acerus, Medac, Aytu Biosci
Profilaktyki nigdy dość - czyli jak śpiewająco zachęcić do samobadania piersi? 🎤🎸🥁 @OnkoCafe @PhilipsFDN @Novartis @AKupiecka @AdriannaSobol #rakpiersi #BreastFit #profilaktyka https://t.co/kfZ8mU4IB0 (Twitter) - Nov 4, 2020
- || Ovastat (treosulfan) / Medac
Clinical, Journal: Treosulfan-Based Conditioning Regimen for Second Allograft in Patients with Myelofibrosis. (Pubmed Central) - Nov 1, 2020
The cumulative incidence of relapse at 5 years was 16%, resulting in a 5-year disease-free and overall survival of 45% and 47%, respectively. Treosulfan-based conditioning for second allograft in relapsed MF patients resulted in about 50% of the patients in long-term freedom from disease.
- | Jivadco (trastuzumab duocarmazine) / Byondis, Medac
New P1 trial, Metastases: ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer (clinicaltrials.gov) - Oct 25, 2020
P1, N=27, Not yet recruiting, Sponsor: QuantumLeap Healthcare Collaborative
- || Campath (alemtuzumab) / Sanofi
Clinical, Journal: Improved transplant survival and long-term disease outcome in children with MHC class II deficiency. (Pubmed Central) - Oct 24, 2020
None had any significant infection or autoimmunity. Changing transplant strategy in our center has significantly improved outcomes for MHC class II deficiency.
- || Natesto (testosterone) / Acerus, Medac, Aytu Biosci
Clinical, Journal: Effect of Natesto on Reproductive Hormones, Semen Parameters and Hypogonadal Symptoms: A Single-Center, Open-Label, Single-Arm Trial. (Pubmed Central) - Oct 24, 2020
Natesto has the potential to be a safe and effective treatment for men with functional hypogonadism who wish to preserve semen parameters. Long-term studies beyond 6 months are needed before we can safely prescribe nasal testosterone gel for men interested in fertility.
- || Natesto (testosterone) / Acerus, Medac, Aytu Biosci, anastrozole / Generic mfg.
Review, Journal: Strategies to increase testosterone in men seeking fertility. (Pubmed Central) - Oct 22, 2020
Recently, a novel therapy, Natesto intranasal testosterone gel, has been shown to increase serum testosterone levels while maintaining semen parameters...Those with low 17-OHP may wish to initiate treatment with alternative therapies, whereas those with high 17-OHP may trial short-acting testosterone therapies. As the urologist's armamentarium continues to increase, better strategies to increase testosterone levels in men seeking fertility can be achieved.
- | Ovastat (treosulfan) / Medac, Medexus
Enrollment change, Trial termination: TrRaMM-TMI: Treosulfan-TMI Conditioning and Rapamycin GvHD Prophylaxis Before Allo-HSCT (clinicaltrials.gov) - Oct 19, 2020
P1, N=9, Terminated, Sponsor: IRCCS San Raffaele
As the urologist's armamentarium continues to increase, better strategies to increase testosterone levels in men seeking fertility can be achieved. N=18 --> 9 | Recruiting --> Terminated; low rate of enrolment
- ||| Natesto (testosterone) / Acerus, Medac, Aytu Biosci
.@ReprodMed Expert session with @ranjithramamd - discussed HCG role for men on testosterone interested in fertility, Natesto trial showing preservation of spermatogenesis and upcoming review of 12-month data #ASRM2020 (Twitter) - Oct 17, 2020
- | Biomarker, Phase classification, PARP Biomarker, PD(L)-1 Biomarker: I-SPY 2: I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (clinicaltrials.gov) - Oct 14, 2020
P1, N=4000, Recruiting, Sponsor: QuantumLeap Healthcare Collaborative
N=18 --> 9 | Recruiting --> Terminated; low rate of enrolment Phase classification: P2 --> P1
- Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca, trastuzumab duocarmazine (SYD985) / Byondis
[VIRTUAL] Her2 low status and response to neoadjuvant chemotherapy in Her2 negative early breast cancer (OnDemand) - Oct 2, 2020 - Abstract #SABCS2020SABCS_370;
There were no substantial differences in demographic/pathologic terms between HER2-low and HER2-0 patients. HER2-low status did not impact pCR rates or RFS of luminal and triple negative tumors treated with neoadjuvant chemotherapy.
- |||| Melblez Kit (melphalan hepatic delivery system) / Delcath
Enrollment closed, Trial completion date, Trial primary completion date: FOCUS: Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma (clinicaltrials.gov) - Sep 28, 2020
P3, N=102, Active, not recruiting, Sponsor: Delcath Systems Inc.
HER2-low status did not impact pCR rates or RFS of luminal and triple negative tumors treated with neoadjuvant chemotherapy. Recruiting --> Active, not recruiting | Trial completion date: Jun 2020 --> Jul 2021 | Trial primary completion date: Apr 2020 --> May 2021
- ||||| Jivadco (trastuzumab duocarmazine) / Byondis, Medac
Enrollment closed, Trial completion date, Trial primary completion date, Metastases: TULIP: SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Sep 23, 2020
P3, N=436, Active, not recruiting, Sponsor: Byondis B.V.
Recruiting --> Active, not recruiting | Trial completion date: Jun 2020 --> Jul 2021 | Trial primary completion date: Apr 2020 --> May 2021 Recruiting --> Active, not recruiting | Trial completion date: May 2021 --> May 2022 | Trial primary completion date: Jul 2020 --> Jul 2021
- || Ovastat (treosulfan) / Medac
Clinical, PK/PD data, Journal: Population pharmacokinetics of treosulfan in pediatric patients undergoing hematopoietic stem cell transplantation. (Pubmed Central) - Sep 23, 2020
This study provides a treosulfan population PK model in children and captures the developmental changes in clearance. A 3-point LSM allows for accurate and precise estimation of treosulfan exposure.
- | Ovastat (treosulfan) / Medac, fludarabine IV / Generic mfg., thiotepa / Generic mfg.
Journal: Haploidentical CD3 or α/β T-cell depleted HSCT in advanced stage sickle cell disease. (Pubmed Central) - Sep 21, 2020
In the T-haplo-HSCT and in the MSD, 20% and 22%, respectively, developed a mild or moderate chronic GvHD. These results demonstrate the feasibility, safety, and efficacy of T-haplo-HSCT also for adult advanced stage SCD patients.
- | thioguanine / Generic mfg.
Trial primary completion date: Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome (clinicaltrials.gov) - Sep 19, 2020
P3, N=256, Recruiting, Sponsor: Children's Oncology Group
These results demonstrate the feasibility, safety, and efficacy of T-haplo-HSCT also for adult advanced stage SCD patients. Trial primary completion date: Mar 2023 --> Jun 2023
- | Xospata (gilteritinib) / Astellas, Vyxeos (cytarabine/daunorubicin liposomal formulation) / Jazz, Nippon Shinyaku, Mylotarg (gemtuzumab ozogamicin) / UCB, PDL, Pfizer
Trial completion date, Trial primary completion date: A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations (clinicaltrials.gov) - Sep 19, 2020
P3, N=1400, Recruiting, Sponsor: Children's Oncology Group
Trial primary completion date: Mar 2023 --> Jun 2023 Trial completion date: Feb 2025 --> Sep 2027 | Trial primary completion date: Feb 2025 --> Sep 2027
- | Ovastat (treosulfan) / Medac, fludarabine IV / Generic mfg., cyclophosphamide intravenous / Generic mfg.
Journal, Combination therapy: Treosulfan in combination with fludarabine as part of conditioning treatment prior to allogeneic hematopoietic stem cell transplantation. (Pubmed Central) - Sep 18, 2020
On the basis of chimerism studies, the Treo-Flu megatherapy lacks full myeloablative potential, but the profound myelosuppression with donor cell-mediated alloreactivity can result in full donor chimerism in the majority of transplant recipients. The clinical studies of allogeneic hematopoietic stem cell transplantation show high heterogeneity, but the safety and feasibility of the Treo-Flu regimen are evident and support its place among reduced-intensity protocols.
- |||| Natesto (testosterone) / Acerus, Medac, Aytu Biosci
Clinical: Thanks @DrMohitKhera for highlighting our #Natesto clinical trial as a "#paradigmshift in T therapy and male fertility" at FUS annual meeting virtually - would have loved to have everyone in person in Miami!! (Twitter) - Sep 12, 2020
- |||| Natesto (testosterone) / Acerus, Medac, Aytu Biosci
Video: Video: Dr Ranjith Ramasamy discusses a recent study evaluating the testosterone nasal gel Natesto https://t.co/ibi7hmhlzI #urology #urologist @ranjithramamd (Twitter) - Sep 11, 2020
- | Ovastat (treosulfan) / Medac, Medexus
Trial completion date, Trial primary completion date: Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies (clinicaltrials.gov) - Sep 9, 2020
P2, N=60, Not yet recruiting, Sponsor: Fred Hutchinson Cancer Research Center
The clinical studies of allogeneic hematopoietic stem cell transplantation show high heterogeneity, but the safety and feasibility of the Treo-Flu regimen are evident and support its place among reduced-intensity protocols. Trial completion date: Dec 2022 --> Dec 2025 | Trial primary completion date: Dec 2022 --> Dec 2023
- || cyclophosphamide intravenous / Generic mfg.
Clinical, Review, Journal: HLA-haploidentical hematopoietic stem cell transplantation in pediatric patients with hemoglobinopathies: current practice and new approaches. (Pubmed Central) - Sep 9, 2020
The preparative regimen for 5 SCD patients included treosulfan/thiotepa/fludarabine/ATG (Berlin pilot cohort)...These data confirm that TCR-α/β+/CD19+ depletion is a well-suited haplo-HSCT strategy for children with hemoglobinopathies. We discuss the results in the context of additional optimization strategies and introduce our concepts for multicenter trial protocols in Germany.
- ||| Natesto (testosterone) / Acerus, Medac, Aytu Biosci
Ranjith Ramasamy, MD, discusses a recent study evaluating the testosterone nasal gel Natesto https://t.co/ibi7hmyWYi #urology #urologist @ranjithramamd @miami_urology (Twitter) - Sep 8, 2020
- everolimus / Generic mfg.
[VIRTUAL] MEPED, a biomodulatory treatment regimen for salvage therapy in relapsed or refractory classic Hodgkin's disease (Abstract video presentations) - Sep 3, 2020 - Abstract #DGHO2020DGHO_2095;
MEPED is well tolerated with low toxicity and highly efficacious in relapsed/refractory cHL, including severely comorbid patients. Due to its immunomodulatory components, MEPED might also have a synergistic potential when combined with ICPi but requires further evaluation within a clinical trial.
- cyclophosphamide intravenous / Generic mfg.
[VIRTUAL] Timely allogeneic blood stem cell transplantation in patients with molecular relapse of NPM1-positive AML (Abstract video presentations) - Sep 3, 2020 - Abstract #DGHO2020DGHO_1678;
Immunosuppression consisted of ATG and Ciclosporin in combination with MTX or MMF and posttransplant Cyclophosphamide for haploidentical HSCT (2 pts)... This analysis shows the efficacy and feasibility of early allogeneic HSCT without reinduction chemotherapy in molecular or early hematological relapse for NPM1- mutated AML pts.
- [VIRTUAL] Comparison of conditioning of melphalan with busulfan or treosulfan before autologous transplantation in AML patients in first remission (Abstract video presentations) - Sep 3, 2020 - Abstract #DGHO2020DGHO_1613;
TreoMel appears to be a safe and feasible alternative regimen for pre-ASCT treatment in AML patients. Considerable interindividual differences in plasma levels were observed for both busulfan and treosulfan, suggesting that pharmacologic monitoring may also be warranted for treosulfan.
- everolimus / Generic mfg.
[VIRTUAL] MEPED, a biomodulatory treatment regimen for salvage therapy in relapsed or refractory classic Hodgkin's disease (Abstract video presentations) - Sep 3, 2020 - Abstract #DGHO2020DGHO_1151;
MEPED is well tolerated with low toxicity and highly efficacious in relapsed/refractory cHL, including severely comorbid patients. Due to its immunomodulatory components, MEPED might also have a synergistic potential when combined with ICPi but requires further evaluation within a clinical trial.
- [VIRTUAL] Comparison of conditioning of melphalan with busulfan or treosulfan before autologous transplantation in AML patients in first remission (Abstract video presentations) - Sep 3, 2020 - Abstract #DGHO2020DGHO_836;
TreoMel appears to be a safe and feasible alternative regimen for pre-ASCT treatment in AML patients. Considerable interindividual differences in plasma levels were observed for both busulfan and treosulfan, suggesting that pharmacologic monitoring may also be warranted for treosulfan.
- everolimus / Generic mfg.
[VIRTUAL] MEPED, a biomodulatory treatment regimen for salvage therapy in relapsed or refractory classic Hodgkin's disease (Abstract video presentations) - Sep 3, 2020 - Abstract #DGHO2020DGHO_334;
MEPED is well tolerated with low toxicity and highly efficacious in relapsed/refractory cHL, including severely comorbid patients. Due to its immunomodulatory components, MEPED might also have a synergistic potential when combined with ICPi but requires further evaluation within a clinical trial.
- cyclophosphamide intravenous / Generic mfg.
[VIRTUAL] Timely allogeneic blood stem cell transplantation in patients with molecular relapse of NPM1-positive AML (Abstract video presentations) - Sep 3, 2020 - Abstract #DGHO2020DGHO_69;
Immunosuppression consisted of ATG and Ciclosporin in combination with MTX or MMF and posttransplant Cyclophosphamide for haploidentical HSCT (2 pts)... This analysis shows the efficacy and feasibility of early allogeneic HSCT without reinduction chemotherapy in molecular or early hematological relapse for NPM1- mutated AML pts.
- [VIRTUAL] Comparison of conditioning of melphalan with busulfan or treosulfan before autologous transplantation in AML patients in first remission (Abstract video presentations) - Sep 3, 2020 - Abstract #DGHO2020DGHO_34;
TreoMel appears to be a safe and feasible alternative regimen for pre-ASCT treatment in AML patients. Considerable interindividual differences in plasma levels were observed for both busulfan and treosulfan, suggesting that pharmacologic monitoring may also be warranted for treosulfan.
- | Ovastat (treosulfan) / Medac, Medexus, Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Enrollment open: Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Thiotepa in Treating Patients With Non-malignant Disorders (clinicaltrials.gov) - Sep 2, 2020
P2, N=40, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Considerable interindividual differences in plasma levels were observed for both busulfan and treosulfan, suggesting that pharmacologic monitoring may also be warranted for treosulfan. Not yet recruiting --> Recruiting
- ||| Ovastat (treosulfan) / Medac
Clinical: Great talk on #treosulfan based conditioning for children by #KrzysztofKalwak #EBMT20Virtual Very low TRM <2% and hardly any VOD 👏👏 (Twitter) - Aug 31, 2020
- || trastuzumab duocarmazine (SYD985) / Byondis, Herceptin (trastuzumab) / Roche
Trastuzumab Duocarmazine Under Exploration in HER2+ Endocrine Cancer @YaleCancer #gynca https://t.co/dpgcbatrDS (Twitter) - Aug 26, 2020
- Ovastat (treosulfan) / Medac
[VIRTUAL] VALUE OF HIGH DOSE CHEMOTHERAPY WITH TREOSULFAN AND MELPHALAN IN PATIENTS WITH DISSEMINATED EWING SARCOMA. REPORT FROM THE INTERNATIONAL EWING 2008R3 TRIAL. (Hall 4) - Aug 26, 2020 - Abstract #SIOP2020SIOP_1197;
P3
HDTreoMel may be of benefit for children aged <14. This observation is comparable to results from the non-randomized trial EE99 R3 (Ladenstein et al.
- Ovastat (treosulfan) / Medac, busulfan / Generic mfg.
[VIRTUAL] SHORT-TERM TOXICITY AFTER BUSULFAN- AND TREOSULFAN-CONTAINING HIGH-DOSE CHEMOTHERAPY REGIMENS IN PEDIATRIC PATIENTS WITH NEUROBLASTOMA, A MATCHED PAIR ANALYSIS (Foyer) - Aug 26, 2020 - Abstract #SIOP2020SIOP_1078;
Conclusions Busulfan- and melphalan-containing conditioning regimen have acceptable toxicity. TreoMel regimen is associated with less frequent severe mucositis, but higher skin toxicity incidence.
- Ovastat (treosulfan) / Medac
[VIRTUAL] RESULTS OF HIGH-DOSE TREOSULFAN-CONTAINING REGIMEN IN PATIENTS WITH HIGH-RISK NEUROBLASTOMA (Foyer) - Aug 26, 2020 - Abstract #SIOP2020SIOP_707;
Conclusions Treosulfan-melphalan regimen was associated with low TRM and safe use in patients who had received MIBG-therapy. Additional studies are needed to assess the long-term prognosis of patients who received treosulfan.
- | Natesto (testosterone) / Acerus, Medac, Aytu BioPharma
Enrollment change: Natesto Effects on Testosterone, Luteinizing Hormone, Follicle Stimulating Hormone and Semen Parameters (clinicaltrials.gov) - Aug 24, 2020
P4, N=71, Completed, Sponsor: University of Miami
Additional studies are needed to assess the long-term prognosis of patients who received treosulfan. N=40 --> 71
- | Spectrila (asparaginase Escherichia coli) / Medac
Trial completion date: PK, PD, Safety and Immunogenicity of Spectrila in Adults With Acute B-cell Lymphoblastic Leukaemia (clinicaltrials.gov) - Aug 24, 2020
P2, N=40, Recruiting, Sponsor: medac GmbH
N=40 --> 71 Trial completion date: Jul 2022 --> Apr 2023
- | Natesto (testosterone) / Acerus, Medac, Aytu Biosci
Effect of Natesto on Reproductive Hormones, Semen Parameters, and Hypogonadal Symptoms https://t.co/hFkQQmIVol via @practiceupdate (Twitter) - Aug 22, 2020
- ||| Natesto (testosterone) / Acerus, Medac, Aytu Biosci
Thanks Dr. @BobbyNajariMD from @NYUUrology for highlighting our study in this month’s AUA News on Natesto increasing T while maintaining sperm parameters in @JUrology with @ranjithramamd and @DrTomMasterson (Twitter) - Aug 15, 2020
- || Natesto (testosterone) / Acerus, Medac, Aytu Biosci
Shame Natesto was pulled from Canadian market in 2019, wonder if they will ever get approved again? At least there are several other testosterone delivery methods and advancements recently. (Twitter) - Aug 11, 2020
- ||| Natesto (testosterone) / Acerus, Medac, Aytu BioPharma
Enrollment open, Adverse events: A Comparison of Side Effects in Hypogonadal Men Treated With Natesto Versus Testosterone Injections (clinicaltrials.gov) - Aug 10, 2020
P4, N=200, Recruiting, Sponsor: University of Miami
Trial completion date: Jul 2022 --> Apr 2023 Not yet recruiting --> Recruiting
- |||| Natesto (testosterone) / Acerus, Medac, Aytu Biosci
Biomarker: Two studies in @JUrology September issue from #ramasamyteam @miami_urology One showing serum 17-OHP can be used as a serum biomarker for intratesticular T and other showing short-acting T therapy w Natesto can maintain spermatogenesis in 95% of men (Twitter) - Aug 8, 2020
- || Natesto (testosterone) / Acerus, Medac, Aytu Biosci
💪 BreastFit: 1000 darmowych badań USG piersi dla 1000 kobiet w Polsce @OnkoCafe @PhilipsFDN @AKupiecka @AdriannaSobol @Novartis #rakpiersi #USG #diagnostyka #BreastFit https://t.co/OTx9vAw7Vy (Twitter) - Aug 7, 2020
- || Ovastat (treosulfan) / Medac, Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health, Norgine, ASKA, Garamycin (gentamicin sulfate) / Generic mfg.
Clinical, Journal: Successful Allogeneic Stem Cell Transplantation in Nuclear Factor-Kappa B Essential Modulator Deficiency Syndrome After Treosulfan-Based Conditioning: A Case Report. (Pubmed Central) - Aug 6, 2020
Patients with NEMO deficiency syndrome require very complex, multidisciplinary care, and immunodeficiency correction can only be observed as one of the critical points in patient care. Developmental problems, enteropathy with the need for intravenous hyperalimentation, and specific interventions for other clinical manifestations of multifaceted syndrome are needed for proper care.